A Look at Teva (NYSE:TEVA) Valuation Following Launch of Europe’s First Lucentis Biosimilar in Pre-Filled Syringe

Teva Pharmaceutical Industries (NYSE:TEVA), along with Formycon AG and Bioeq AG, has launched FYB201/Ranivisio in Europe as the first Lucentis biosimilar available in an EMA-approved pre-filled syringe. This move highlights Teva’s focus on innovation and its ongoing efforts to strengthen its ophthalmology offerings. See our latest analysis for Teva Pharmaceutical Industries. The recent European launch of FYB201/Ranivisio appears to have given Teva’s share price some renewed momentum, with a…Read More